2020
Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib
Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunocompromised HostLymphoma, T-CellMaleMiddle AgedNitrilesPandemicsPneumonia, ViralPyrazolesPyrimidinesSARS-CoV-2Severity of Illness IndexTransplantation, HomologousTreatment OutcomeConceptsAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant patientsSevere acute respiratory syndrome coronavirus 2SARS coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 pneumoniaAcute respiratory syndrome coronavirus 2Stem cell transplant patientsSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Coronavirus 2 infectionCell transplant patientsCoV-2 infectionStem cell transplantationSyndrome coronavirus 2High death rateImmunocompromised stateJAK/STAT inhibitor ruxolitinibTransplant patientsCell transplantationCoronavirus 2Novel therapiesInhibitor ruxolitinibPatientsDeath rateRuxolitinib
2019
Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
O’Connor O, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d’Amore F, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR, . Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. Journal Of Clinical Oncology 2019, 37: 613-623. PMID: 30707661, PMCID: PMC6494247, DOI: 10.1200/jco.18.00899.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAurora Kinase AAzepinesDisease ProgressionDisease-Free SurvivalDrug Resistance, NeoplasmEarly Termination of Clinical TrialsFemaleHumansLymphoma, T-Cell, PeripheralMaleMiddle AgedProtein Kinase InhibitorsPyrimidinesRecurrenceTime FactorsYoung AdultConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaProgression-free survivalOverall response rateT-cell lymphomaComparator armInvestigational Aurora A kinase inhibitorResponse rateMedian progression-free survivalTwo-year overall survivalRandomized phase III studyRandomized phase III trialIndependent data monitoring committeeEfficacy of alisertibMore prior therapiesSingle-agent comparatorCommon adverse eventsPhase III studyPhase III trialsIndependent central reviewData monitoring committeeDrug discontinuationIntravenous romidepsinOral alisertibPrior therapy